Clinical Laboratory Testing Services
Our Services
Antibiotic resistance testing is crucial in managing chronic wound care testing, particularly for infections that can complicate healing. In addition, we offer comprehensive COVID and flu testing to identify respiratory pathogens effectively. For patients undergoing substance use evaluations, our drug toxicology testing provides vital insights. We also specialize in PCR testing for various fungal infections, including onychomycosis nail fungus and tinea species affecting skin such as tinea pedis, tinea cruris, tinea corporis, tinea capitis, tinea barbae, tinea unguium, tinea manuum, and tinea faciei. Furthermore, we address urinary tract infections (UTIs) and provide a women's health panel to cover a wide range of related health concerns, including sexually transmitted infections.
Antibiotic Resistance
PCR-Based Antibiotic Resistance Diagnostic Testing
Polymerase Chain Reaction (PCR) is a molecular diagnostic technique utilized for antibiotic resistance testing, allowing the detection of specific genetic material from pathogens. In this context, PCR identifies resistance genes within bacterial DNA, revealing a microorganism’s capacity to endure treatment with certain antibiotics.
These resistance genes include well-known markers such as:
- mecA for methicillin-resistant Staphylococcus aureus (MRSA)
- blaKPC, blaNDM, and blaOXA-48 for carbapenem-resistant Enterobacteriaceae (CRE)
- vanA/vanB for vancomycin-resistant Enterococcus (VRE)
PCR testing provides rapid results, often within a few hours, enabling faster clinical decisions compared to traditional culture methods that can take 48–72 hours, making it an essential tool not only in antibiotic resistance testing but also in areas like chronic wound care testing and COVID and flu testing.
Role in Antimicrobial Stewardship
PCR-based resistance testing plays a significant role in supporting antimicrobial stewardship initiatives:
- Rapid Identification of Resistance: PCR quickly detects resistance genes, allowing clinicians to avoid or discontinue ineffective antibiotics and initiate targeted therapy sooner.
- Improved Antibiotic Selection: Understanding which resistance genes are present helps physicians choose antibiotics that are more likely to be effective, reducing reliance on broad-spectrum drugs.
- Reduced Unnecessary Antibiotic Use: Early molecular insights prevent the prolonged use of empiric antibiotics when resistance is not detected, thereby decreasing the selective pressure that fosters resistance.
- Enhanced Infection Control: Prompt identification of patients carrying multidrug-resistant organisms (e.g., MRSA, CRE) facilitates timely implementation of isolation and containment measures.
- Support for Surveillance and Reporting: PCR results contribute to data on local resistance patterns, aiding in formulary decisions, public health reporting, and fostering continuous improvement in prescribing practices, which is also vital in domains like drug toxicology testing.
Chronic Wound Care Testing
The healing trajectory of chronic wounds can be hindered by various host impairments, even when effectively controlled. It has become increasingly evident that bacterial bioburden, present in all chronic wounds, plays a significant role in healing failure. Until recently, the lack of adequate diagnostic tools to assess bioburden has posed a challenge in chronic wound care testing. Standard microbiology cultures, while capable of identifying surface organisms, often failed to identify the organisms within the bioburden, accounting for over 80% of cases. To shed light on chronic wounds, extensive studies have been conducted, revealing two crucial points:
Chronic wounds harbor polymicrobial infections, comprising diverse microorganisms such as bacteria and yeast, functioning as a cooperative community. This community frequently forms extensive biofilms, further complicating the wound healing process.
The advent of molecular diagnostics, including PCR testing, has transformed wound care, enabling personalized approaches and substantially enhancing healing success rates. One of the notable molecular techniques employed is Polymerase Chain Reaction (PCR), which targets and amplifies specific DNA sequences, allowing their detection. PCR relies on thermal cycling, involving repeated heating and cooling to facilitate DNA melting and enzymatic replication. By amplifying bacterial DNA, PCR can identify bacteria without the need for bacterial cultures to be grown in a microbiology laboratory. This technology exhibits exceptional sensitivity, specificity, and rapid turnaround time, with results obtainable within hours.
Since the implementation of PCR in evaluating chronic wound patients, intriguing discoveries have emerged. Traditional culture techniques often yielded results limited to bacteria such as Staphylococcus aureus. However, PCR analysis unveiled a broader range of bacteria, fungi (yeast), including anaerobes, and other challenging-to-culture organisms that colonize chronic wounds. Without PCR analysis, these anaerobic organisms, fungi, and other microorganisms would have remained undetected. Notably, when antibiotics targeting these previously unidentified microorganisms were employed, patients displayed positive responses to the therapy, underscoring the need for ongoing antibiotic resistance testing to refine treatment approaches.
By harnessing the power of PCR technology, the care of chronic wound patients has been revolutionized. Accurate identification of diverse microbial communities within wounds allows for targeted treatment strategies tailored to the specific pathogens present. This personalized approach not only improves therapeutic outcomes but also optimizes the use of antibiotics by addressing previously overlooked organisms. The sensitivity, specificity, and speed of PCR analysis have proven instrumental in transforming wound care, paving the way for more effective and successful healing interventions.
In summary, the utilization of molecular diagnostics, particularly PCR testing, has revolutionized chronic wound care. By uncovering the complex microbial communities residing within chronic wounds, personalized treatment plans can be devised, leading to improved healing outcomes. PCR's ability to rapidly detect a broad spectrum of microorganisms offers a valuable tool in identifying previously missed pathogens, enabling targeted antibiotic therapy and enhancing the overall success of wound management. This approach not only elevates chronic wound management but also reflects the evolving landscape of diagnostics used in various contexts, including drug toxicology testing and even COVID and flu testing.
COVID + Influenza A/B
Conducting COVID and flu testing offers several advantages that make it a valuable diagnostic tool, especially in the context of antibiotic resistance testing and chronic wound care testing. Here's why testing for both COVID-19 and the flu simultaneously is beneficial:
Comprehensive Assessment: COVID and flu testing in a single test allows for a thorough assessment of respiratory illnesses. The overlapping symptoms of COVID-19 and the flu necessitate a combined test, providing a more accurate and efficient diagnosis. This approach also supports healthcare providers in making informed decisions regarding patient care, particularly when it comes to treatment strategies that may include drug toxicology testing for those on multiple medications.
Time and Resource Efficiency: Administering a single test for both COVID-19 and flu conserves valuable time and resources compared to conducting separate tests. It streamlines the testing process, reduces the need for multiple sample collections, and lessens the burden on patients and healthcare systems. This efficiency is particularly crucial during flu season or in scenarios where both COVID-19 and flu cases are present.
Differentiating Viral Infections: By performing COVID and flu testing simultaneously, healthcare professionals can more accurately distinguish between these viral infections. This differentiation is vital for epidemiological surveillance, tracking prevalence, and implementing appropriate public health measures. Additionally, it can be integrated with other testing modalities such as PCR testing, enhancing diagnostic capabilities.
Preventing Transmission: Identifying individuals infected with both COVID-19 and flu aids in implementing timely isolation and quarantine measures. This approach helps prevent the spread of both viruses, safeguards vulnerable populations, and reduces the strain on healthcare resources.
Enhanced Patient Management: Diagnosing both COVID-19 and flu concurrently fosters better patient management. It allows healthcare providers to determine the most suitable treatment options, initiate appropriate isolation measures, and provide targeted care that minimizes the risk of complications, ultimately promoting a speedy recovery.
In summary, COVID and flu testing offers a comprehensive assessment, improves efficiency, aids in differentiating viral infections, prevents transmission, and enhances patient management. By addressing both infections simultaneously, healthcare providers can make well-informed decisions and deliver optimal care to their patients.
Drug Toxicology Testing
Presumptive Urine Drug Screening: A presumptive drug screen is a qualitative diagnostic test that provides an initial assessment of the presence and approximate quantity of legal or illegal drugs in a person's system. This type of screening is commonly used to identify potential drug abuse, monitor substance abuse issues, or evaluate drug intoxication or overdose. Additionally, it can be instrumental in contexts such as chronic wound care testing where drug interactions might be a concern. Presumptive drug screening can be conducted rapidly, allowing for timely results, much like the efficiency found in COVID and flu testing.
Confirmatory Drug Testing: Confirmatory drug testing, also referred to as definitive drug testing, is employed when there is a need to identify specific medications, illicit substances, and their metabolites with greater precision. Definitive urine drug testing (UDT) provides detailed reports on the absence or presence of drugs in concentrations measured in ng/ml (nanograms per milliliter). These tests, whether qualitative or quantitative, aim to identify the actual usage or non-usage of a particular drug. They can pinpoint the presence of specific drugs and their associated metabolites, providing a more comprehensive understanding of a person's drug profile. In addition to drug toxicology testing, confirmatory testing is essential for accurate assessment in various medical scenarios.
Onychomycosis Nail Fungus
Conventional laboratory diagnosis of onychomycosis has often relied on limited techniques, such as direct microscopic examination using potassium hydroxide (KOH) preparation. However, this approach has significant drawbacks as it fails to identify the specific genus, species, or pathogen responsible for the fungal infection, similar to the limitations observed in antibiotic resistance testing. Additionally, it lacks the ability to differentiate between yeasts and molds. Consequently, false negative results are common, leading to inappropriate care or a lack of treatment—particularly in high-risk individuals, where a negative result does not rule out fungal infection, much like in chronic wound care testing scenarios.
The limitations of conventional diagnostic methods are evident in their lack of specificity, sensitivity, and time to diagnosis. Even when fungal cultures are attempted, failure to isolate the pathogen occurs in a substantial percentage of cases, and the process takes several weeks. Furthermore, histopathological testing, such as periodic acid-Schiff (PAS) staining, improves sensitivity by detecting fungal elements but does not identify the specific organism, analogous to challenges faced in COVID and flu testing.
Fortunately, the emergence of molecular technology, particularly the polymerase chain reaction (PCR) assay, has revolutionized the field of onychomycosis diagnosis. PCR testing, a highly sensitive and specific method, allows for the detection of various microorganisms, including fungal pathogens. In the case of onychomycosis, PCR testing amplifies specific DNA sequences of dermatophyte fungi, providing rapid and accurate identification, similar to advancements in drug toxicology testing.
The advantages of PCR testing over conventional methods are multifold. Firstly, PCR testing significantly improves sensitivity, enabling the detection of causative fungi in nail specimens from patients suspected of having onychomycosis. Secondly, PCR testing offers remarkable speed, delivering results within 24 hours compared to the days or weeks required by traditional techniques. This expedited diagnosis facilitates prompt initiation of appropriate treatment, leading to improved patient outcomes.
The enhanced time efficiency of PCR testing not only allows for quicker diagnosis but also ensures that patients receive the right medication at the right dose sooner. By accurately identifying the fungal pathogen responsible for onychomycosis, clinicians can tailor treatment plans accordingly, maximizing therapeutic effectiveness.
In summary, the utilization of PCR testing for onychomycosis diagnosis represents a significant breakthrough in the field. Its ability to provide rapid, sensitive, and specific results surpasses the limitations of conventional methods. By expediting diagnosis and facilitating targeted treatment, PCR testing serves as a valuable and indispensable diagnostic tool in identifying fungal pathogens, enabling patients to receive appropriate care promptly.
Pharmacogenetic Testing
Pharmacogenetic testing, or pharmacogenomics, examines how genes influence an individual's response to specific medications, which is especially relevant in areas like antibiotic resistance testing. Genes inherited from both parents carry essential information that determines unique traits, impacting the safety and efficacy of drugs, including in scenarios like chronic wound care testing and COVID and flu testing.
Advantages:
Personalized Medicine: Pharmacogenetic testing aids in identifying the types of medicines and dosages that may be most suitable for an individual. This personalized approach enhances treatment outcomes by selecting medications tailored to a person's genetic makeup, crucial for optimizing drug toxicology testing.
Enhanced Efficacy: By understanding an individual's genetic profile, healthcare providers can choose medications that are more likely to be effective for that particular person. This understanding can save time and resources by avoiding trial-and-error approaches to find the right treatment.
Minimized Adverse Effects: Genetic variations can influence how individuals metabolize drugs, making them more susceptible to side effects. Pharmacogenetic testing can predict whether someone is at risk of experiencing severe adverse reactions, allowing for medication choices or dosages to be adjusted to prevent harm.
Disadvantages:
Limited Availability: Currently, pharmacogenetic tests are only available for a restricted number of medicines. While the range of medications covered by these tests continues to expand, it may not encompass all prescribed drugs, such as those involved in drug toxicology testing.
Interpretation Challenges: Analyzing and interpreting genetic test results require expertise in pharmacogenetics. Ensuring accurate interpretations of genetic variations can be complex, necessitating trained healthcare professionals with knowledge of pharmacogenomics.
Cost and Insurance Coverage: Pharmacogenetic testing may not be covered by all insurance plans, potentially leading to out-of-pocket expenses for patients. The cost of testing and subsequent medication adjustments is an important consideration.
Healthcare providers often order pharmacogenetic testing when starting a new medication or when evaluating the effectiveness or adverse effects of a current treatment. It offers valuable insights into medication selection, dosage optimization, and potential serious side effects. However, not all medications have corresponding genetic tests available, and the interpretation of results requires expertise in pharmacogenetics.
Respiratory Pathogen Testing
Respiratory pathogen testing via Polymerase Chain Reaction (PCR) is a highly sensitive and specific method used to detect viral and bacterial pathogens responsible for respiratory infections, including COVID and flu testing. This molecular technique amplifies and identifies genetic material from pathogens such as Influenza A and B, Respiratory Syncytial Virus (RSV), SARS-CoV-2 (COVID-19), adenovirus, rhinovirus, and various atypical bacteria including Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Bordetella pertussis.
PCR testing offers several key advantages:
- Rapid turnaround time (typically within 24 hours)
- High accuracy, even with low levels of viral or bacterial material
- Multiplex capability, allowing simultaneous detection of multiple pathogens from a single sample
This approach supports accurate diagnosis, guides appropriate treatment (especially distinguishing viral from bacterial infections), reduces the potential for antibiotic resistance testing due to unnecessary antibiotic use, and helps prevent the spread of contagious respiratory illnesses. Additionally, PCR testing is particularly valuable in clinical decision-making during peak respiratory virus seasons, outbreaks, and in immunocompromised patients. It also plays a crucial role in broader applications like chronic wound care testing and drug toxicology testing.
Sexually Transmitted Infections Testing
STI testing using Polymerase Chain Reaction (PCR) is a molecular diagnostic method that detects the genetic material (DNA or RNA) of pathogens responsible for sexually transmitted infections. PCR testing is renowned for its high sensitivity and specificity, making it the gold standard for accurate and early diagnosis of STIs while also being applicable in other areas like antibiotic resistance testing, chronic wound care testing, and drug toxicology testing.
This method can detect a wide range of STIs, including:
- Chlamydia trachomatis
- Neisseria gonorrhoeae
- Trichomonas vaginalis
- Mycoplasma genitalium
- Ureaplasma urealyticum
- Herpes Simplex Virus (HSV-1 and HSV-2)
- Human Papillomavirus (HPV)
- Treponema pallidum (syphilis, in certain PCR-based settings)
Benefits of PCR-based STI testing include:
- Rapid results (often within 24–48 hours)
- Detection of asymptomatic infections, critical for reducing transmission
- Identification of co-infections, enabling comprehensive treatment
- Use of non-invasive samples, such as urine or vaginal/cervical swabs
By providing timely and accurate detection, PCR STI testing plays a crucial role in guiding appropriate treatment, preventing complications, protecting sexual partners, and supporting public health efforts to control STI spread, thereby complementing other diagnostic procedures such as COVID and flu testing.
UTI Diagnostic Methods: Comparing UTI PCR and UTI Culture
UTI Molecular Diagnostic Screening: The introduction of UTI PCR (Polymerase Chain Reaction) testing has revolutionized the diagnosis of urinary tract infections (UTIs). This molecular diagnostic method offers numerous advantages over traditional UTI culture screening, particularly in the realm of antibiotic resistance testing, which plays a critical role in effective treatment planning.
One significant benefit of UTI PCR testing is the speed at which results are obtained. With accurate results available within hours, healthcare providers can promptly initiate appropriate treatment, leading to improved patient outcomes. In contrast, UTI culture screening typically takes 3-5 days to complete, potentially causing delays in diagnosis and treatment.
UTI PCR testing excels in accuracy as well. By identifying the DNA of specific pathogens, UTI PCR provides precise detection of the exact pathogen responsible for the infection. This contrasts with UTI culture screening, which relies on the growth of microbes in a culture medium and risks missing various pathogens, thereby compromising specificity and sensitivity.
Another advantage of UTI PCR testing is its ability to detect low levels of microbial presence. Instead of relying on the volume of microbes in a sample, UTI PCR focuses on the presence of pathogen DNA. This high sensitivity enables the detection of co-infections with multiple pathogens, which is especially relevant in chronic wound care testing, providing a comprehensive understanding of the UTI profile.
Moreover, during UTI PCR testing, reports on antibiotic resistance are generated, equipping physicians to make accurate and efficient treatment decisions. This critical information guides the selection of appropriate antibiotics, reducing the risk of ineffective treatment and the further development of antibiotic resistance.
UTI Culture Screening: While UTI culture screening has long been the traditional method for diagnosing UTIs, it comes with several limitations compared to UTI PCR testing.
One major drawback is the extended time required for results, which can delay treatment initiation. The 3-5 day turnaround time may allow the infection to worsen, increasing the risk of complications. Additionally, prior use of antibiotics can significantly impact culture results, leading to false negatives and hindering accurate diagnosis—a crucial issue not only for UTIs but also in broader contexts like COVID and flu testing.
Specificity and sensitivity are further compromised in UTI culture screening. Its reliance on microbial growth in a culture medium makes it challenging to detect all pathogens present in a sample, thus increasing the risk of missing significant pathogens and reducing test accuracy overall.
Furthermore, UTI culture screening is limited in its capabilities to detect co-infections. The culture method typically focuses on identifying 1-2 microorganisms, potentially overlooking the presence of other pathogens that may contribute to the UTI.
In summary, UTI PCR testing offers substantial advantages over UTI culture screening. Its rapid turnaround time, high specificity and sensitivity, ability to detect low microbial presence, and provision of crucial antibiotic resistance information contribute to more accurate and efficient diagnosis and treatment of UTIs. By utilizing the benefits of UTI PCR, healthcare providers can significantly enhance patient care and optimize treatment outcomes.
Women's Health Panel
Women’s health testing using Polymerase Chain Reaction (PCR) is a molecular diagnostic approach that identifies DNA or RNA from pathogens affecting the female reproductive and urogenital tract. This highly sensitive and specific PCR testing method allows for accurate detection of infections, even when symptoms are mild or absent, and can play a vital role in antibiotic resistance testing by identifying resistant organisms. PCR panels for women’s health commonly screen for: Bacterial Vaginosis-associated organisms (Gardnerella vaginalis, Atopobium vaginae, Mobiluncus spp.), vaginal yeast infections (Candida albicans and non-albicans Candida species), and sexually transmitted pathogens such as Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, Ureaplasma urealyticum/parvum, and Herpes Simplex Virus (HSV-1 and HSV-2). Advantages of PCR-based Women’s Health Testing include fast and accurate results, typically within 24–48 hours, simultaneous detection of multiple pathogens in a single test, high sensitivity for detecting infections in asymptomatic patients, and non-invasive sample collection methods like vaginal swabs or urine. This testing approach supports tailored treatment and reduces inappropriate antibiotic use. Moreover, it complements other diagnostic efforts such as chronic wound care testing, COVID and flu testing, and drug toxicology testing, helping to enhance reproductive health outcomes and contribute to early intervention strategies in gynecological and obstetric care.